178 related articles for article (PubMed ID: 36090975)
21. B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33.
Arima H; Nishikori M; Otsuka Y; Kishimoto W; Izumi K; Yasuda K; Yoshimoto T; Takaori-Kondo A
Blood Adv; 2018 Sep; 2(18):2282-2295. PubMed ID: 30213787
[TBL] [Abstract][Full Text] [Related]
22. Cbl-b regulates antigen-induced TCR down-regulation and IFN-gamma production by effector CD8 T cells without affecting functional avidity.
Shamim M; Nanjappa SG; Singh A; Plisch EH; LeBlanc SE; Walent J; Svaren J; Seroogy C; Suresh M
J Immunol; 2007 Dec; 179(11):7233-43. PubMed ID: 18025165
[TBL] [Abstract][Full Text] [Related]
23. Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
Bu N; Wu H; Zhang G; Zhan S; Zhang R; Sun H; Du Y; Yao L; Wang H
J Mol Neurosci; 2015 Jul; 56(3):631-43. PubMed ID: 25680514
[TBL] [Abstract][Full Text] [Related]
24. Establishment of the major compatibility complex-dependent development of CD4+ and CD8+ T cells by the Cbl family proteins.
Huang F; Kitaura Y; Jang I; Naramura M; Kole HH; Liu L; Qin H; Schlissel MS; Gu H
Immunity; 2006 Oct; 25(4):571-81. PubMed ID: 17045823
[TBL] [Abstract][Full Text] [Related]
25. Deltex1 promotes protein kinase Cθ degradation and sustains Casitas B-lineage lymphoma expression.
Hsu TS; Hsiao HW; Wu PJ; Liu WH; Lai MZ
J Immunol; 2014 Aug; 193(4):1672-80. PubMed ID: 25000980
[TBL] [Abstract][Full Text] [Related]
26. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
Steingold JM; Hatfield SM
Front Immunol; 2020; 11():570041. PubMed ID: 33117358
[TBL] [Abstract][Full Text] [Related]
27. Releasing the brake: targeting Cbl-b to enhance lymphocyte effector functions.
Wallner S; Gruber T; Baier G; Wolf D
Clin Dev Immunol; 2012; 2012():692639. PubMed ID: 22550535
[TBL] [Abstract][Full Text] [Related]
28. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
29. Adenosine A2A Receptor Stimulation Inhibits TCR-Induced Notch1 Activation in CD8+T-Cells.
Sorrentino C; Hossain F; Rodriguez PC; Sierra RA; Pannuti A; Osborne BA; Minter LM; Miele L; Morello S
Front Immunol; 2019; 10():162. PubMed ID: 30792717
[TBL] [Abstract][Full Text] [Related]
30. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
[TBL] [Abstract][Full Text] [Related]
31. Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.
Xi M; Guo S; Bayin C; Peng L; Chuffart F; Bourova-Flin E; Rousseaux S; Khochbin S; Mi JQ; Wang J
Front Med; 2022 Jun; 16(3):442-458. PubMed ID: 34669156
[TBL] [Abstract][Full Text] [Related]
32. Silencing the expression of Cbl-b enhances the immune activation of T lymphocytes against RM-1 prostate cancer cells in vitro.
Zhou SK; Chen WH; Shi ZD; Wang SP; Li L; Wen XF; Wang YM
J Chin Med Assoc; 2014 Dec; 77(12):630-6. PubMed ID: 25249301
[TBL] [Abstract][Full Text] [Related]
33. Lunatic Fringe prolongs Delta/Notch-induced self-renewal of committed αβ T-cell progenitors.
Yuan JS; Tan JB; Visan I; Matei IR; Urbanellis P; Xu K; Danska JS; Egan SE; Guidos CJ
Blood; 2011 Jan; 117(4):1184-95. PubMed ID: 21097675
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
35. Tumor Arrests DN2 to DN3 Pro T Cell Transition and Promotes Its Conversion to Thymic Dendritic Cells by Reciprocally Regulating Notch1 and Ikaros Signaling.
Guha I; Bhuniya A; Shukla D; Patidar A; Nandi P; Saha A; Dasgupta S; Ganguly N; Ghosh S; Nair A; Majumdar S; Saha B; Storkus WJ; Baral R; Bose A
Front Immunol; 2020; 11():898. PubMed ID: 32582141
[TBL] [Abstract][Full Text] [Related]
36. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
37. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
38. Uniform expression of Notch1, suppressor of B-cell-specific gene expression, in plasmablastic lymphoma.
Seegmiller AC; Wang HY; Hladik C; Chen W
Arch Pathol Lab Med; 2011 Jun; 135(6):770-5. PubMed ID: 21631271
[TBL] [Abstract][Full Text] [Related]
39. Notches, NFkappaBs and the making of T cell leukemia.
Aifantis I; Vilimas T; Buonamici S
Cell Cycle; 2007 Feb; 6(4):403-6. PubMed ID: 17329966
[TBL] [Abstract][Full Text] [Related]
40. E3 ubiquitin ligase Casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapy.
Jafari D; Mousavi MJ; Keshavarz Shahbaz S; Jafarzadeh L; Tahmasebi S; Spoor J; Esmaeilzadeh A
Clin Exp Immunol; 2021 Apr; 204(1):14-31. PubMed ID: 33306199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
